Switch theme
Sign up to access all valuation multiples
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
2021
140
LTM Revenue n/a
LTM EBITDA -$51.5M
$58.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rani Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$51.5M.
In the most recent fiscal year, Rani Therapeutics achieved revenue of n/a and an EBITDA of -$62.0M.
Rani Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rani Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$61.7M | -$62.0M | -$50.9M | -$51.5M | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -Infinity% | XXX |
| Net Profit | -$8.3M | -$30.6M | -$34.0M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | $2.1M | $23.5M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Rani Therapeutics's stock price is $2.
Rani Therapeutics has current market cap of $55.3M, and EV of $58.6M.
See Rani Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $58.6M | $55.3M | XXX | XXX | XXX | XXX | $-1.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Rani Therapeutics has market cap of $55.3M and EV of $58.6M.
Rani Therapeutics's trades at n/a LTM EV/Revenue multiple, and -1.1x LTM EBITDA.
Analysts estimate Rani Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Rani Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $58.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | XXX | XXX |
| P/E | -1.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRani Therapeutics's NTM/LTM revenue growth is Infinity%
Rani Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Rani Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Rani Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Rani Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rani Therapeutics acquired XXX companies to date.
Last acquisition by Rani Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Rani Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Rani Therapeutics founded? | Rani Therapeutics was founded in 2021. |
| Where is Rani Therapeutics headquartered? | Rani Therapeutics is headquartered in United States of America. |
| How many employees does Rani Therapeutics have? | As of today, Rani Therapeutics has 140 employees. |
| Who is the CEO of Rani Therapeutics? | Rani Therapeutics's CEO is Mr. Talat Imran. |
| Is Rani Therapeutics publicy listed? | Yes, Rani Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Rani Therapeutics? | Rani Therapeutics trades under RANI ticker. |
| When did Rani Therapeutics go public? | Rani Therapeutics went public in 2021. |
| Who are competitors of Rani Therapeutics? | Similar companies to Rani Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rani Therapeutics? | Rani Therapeutics's current market cap is $55.3M |
| What is the current EBITDA of Rani Therapeutics? | Rani Therapeutics's last 12-month EBITDA is -$51.5M. |
| What is the current EV/EBITDA multiple of Rani Therapeutics? | Current EBITDA multiple of Rani Therapeutics is -1.1x. |
| Is Rani Therapeutics profitable? | Yes, Rani Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
